"id","uuid:ID","instanceType","label","rationale","description","name"
"StudyDesign_1","a5875cc0-13a6-499d-9fc9-3dad2761430d","StudyDesign","","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","The main design for the study","Study Design 1"
